Skip to content
CleaStart with Clea
Australia’s clearer way into migraine care.See how Clea works
Start with Clea
All treatmentsAcute · NSAID

Naproxen

Naproxen is one option discussed in migraine care. Clea explains where it sits in the treatment landscape without recommending it for an individual person.

Checking review recordSource references are available below.
ROLE BY HEADACHE TYPE

Which patterns is this used for?

Frequency and symptoms can overlap: someone can have chronic migraine and vestibular symptoms, for example. Choose a label to explore usual roles, not to select a treatment for yourself.

General information, not personal medical advice. Some uses are off-label or supported by limited evidence. TGA approval, PBS eligibility and individual suitability differ. Do not start, stop or change treatment without your clinician or pharmacist.

Menstrual-related migraine

Short-term prevention · Specialist use / limited evidence

Sometimes considered around predictable cycle-linked attacks. The medicine, timing and whether this is off-label need a prescriber-led plan.

NICE headache guideline: migraine and cluster headache

Use labels are an editorial guide to the cited sources, not a clinical recommendation or an independent clinical-review badge. Each profile retains its separate review status.

ROLE IN CARE

Where it fits

Acute treatment and sometimes short-term strategies discussed by clinicians.

HOW IT IS USED

Administration

Oral medicine.

EVIDENCE

What we know

Established NSAID option with evidence in acute migraine.

AUSTRALIA

Access

Available in Australia.

HOW THE CLASS WORKS

Mechanism, in plain language.

NSAIDs reduce prostaglandin production through cyclo-oxygenase pathways. In migraine they are used as acute medicines in selected people, but the same class effects that make them useful also create gastrointestinal, kidney and cardiovascular precautions.

HOW TO JUDGE RESPONSE

Decide what “working” would mean.

For an acute treatment, useful questions include how reliably it improves the attack, how quickly function returns, whether symptoms recur, whether rescue treatment is still needed and how many days per month the medicine is used. Frequent use also matters because medication-overuse risk depends partly on medicine class and days of use.

WHAT TO ASK

Questions for the treatment conversation

  • What is the goal of using Naproxen in my migraine plan?
  • How will we decide whether it is helping enough to continue?
  • What side effects or warning signs should I know about?
  • Do any of my other medicines, conditions, pregnancy plans or allergies change the discussion?
  • What is the current Australian access pathway and likely cost for me?
WHAT TO TRACK

Give the next review better evidence.

Before and after a treatment change, record migraine-like days, total headache days, acute medicine days, severity and functional impact. If you notice side effects, record what happened and when rather than relying on memory at the next appointment.

Add to My Treatments
SAFETY

Suitability is individual.

NSAID precautions apply, including gastrointestinal, kidney and cardiovascular risk.

Clea does not recommend, start, stop or change medicines. Discuss individual treatment decisions with your GP, neurologist, pharmacist or other treating clinician.

DRUGS.COM · EXTERNAL PATIENT REVIEWS

Read the right review category.

Original Drugs.com ratings use a 10-point scale. Read the source condition label and review count before drawing conclusions. “Migraine Prevention” is not a vestibular-only or episodic-only score, and a review category does not establish an approved indication.

Source links only. Clea has not imported ratings or review text. Republishing source scores requires permission; no licensed ratings feed is connected. Drugs.com is US-focused, so medicine names and approved uses may differ from Australia. Reviews are self-selected experiences, not comparative evidence of effectiveness.

CLEA COMMUNITY EXPERIENCE · NOT DRUGS.COM

Compare experiences from the same pattern.

People can report a migraine frequency and a symptom pattern separately, such as chronic plus vestibular. Labels are self-reported, not independently diagnosed or verified. Groups can overlap and cannot establish that one treatment works better than another.

Viewing: All migraine frequencies · All symptom patterns

Loading this group…

Small, self-selected groups are not clinical trials. Scores are perceived experiences and may reflect dose, treatment duration, other conditions and access as well as benefit. No personal identities are published here.

Log in to add your experience
SOURCES & CURRENT ACCESS

Check the original source.

Therapeutic Goods AdministrationPharmaceutical Benefits SchemeMigraine & Headache Australia drug directory

Keep your treatment story in one place.

Add treatments you have tried to My Clea, then use your history when preparing for your next appointment.

Open My Clea